MedPath

ToxIVIG Study - Effect of Immunoglobulins on Mortality in Children with Toxic Shock Syndrome

Conditions
A40.0
Sepsis due to streptococcus, group A
Registration Number
DRKS00034536
Lead Sponsor
Kinderklinik I, Universitätsmedizin Essen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
322
Inclusion Criteria

Timeframe: Admission between January 1, 2016, and December 31, 2023.
Age at admission = 28 days and < 18 years
Screening: ICD-10 codes A40.0, A41.0, A48.3, R57.2;
Inclusion: all cases with A48.3 + all other cases clinically meeting inclusion criteria for TSS

Exclusion Criteria

none

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evaluation of the Effect of Intravenous Immunoglobulins on Mortality in Children with Toxic Shock Syndrome
Secondary Outcome Measures
NameTimeMethod
Evaluation of the effect of intravenous immunoglobulins in children with toxic shock syndrome on outcomes other than mortality.
© Copyright 2025. All Rights Reserved by MedPath